Venom-Derived Enzyme Inhibitors as Anticancer Agents: Structure–Activity Relationships, Molecular Targets and Mechanistic Insights
Molecules · 2026
DOI: 10.3390/molecules31132398 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2026. Verfasst von Ayorinde Victor Ogundele und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Ciencias Basicas, Facultad de Medicina, Universidad de La Frontera, Temuco 4780000, Chile. Hauptthemen laut MEDLINE: Antineoplastic Agents, Venoms, Enzyme Inhibitors, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 235 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigación y Desarrollo, ANID Chile, Universidad de La Frontera, Temuco, Chile.
Abstract (Originalsprache)
Animal venoms represent an extraordinary, yet largely untapped, biochemical reservoir for oncological drug discovery. This review provides a comprehensive analysis of venom-derived enzyme inhibitors as emerging anticancer agents, emphasizing their chemical diversity, structure–activity relationships (SAR), molecular targets, and mechanistic pathways. Venom-derived peptides and proteins exhibit exceptional binding affinity and structural rigidity, characteristics frequently enforced by conserved disulfide networks. This specific architecture allows them to selectively modulate critical cancer-associated enzymes, including matrix metalloproteinases, phospholipases A2, serine proteases, and kinases. Inhibiting these highly specific targets successfully disrupts tumour angiogenesis, extracellular matrix remodelling, and metastatic dissemination, while simultaneously inducing apoptosis through unique pathways such as reactive oxygen species generation. Modern computational approaches, encompassing deep learning algorithms, molecular docking, and molecular dynamics simulations, are substantially accelerating and transforming the discovery pipeline by rapidly mapping intricate peptide–receptor interactions and guiding rational drug design. Translating these potent molecules into clinical therapeutics remains heavily challenged by pharmacokinetic instability, rapid proteolytic degradation, and systemic toxicity. The integration of computationally optimized scaffolds with advanced targeted delivery platforms, such as nanocarriers and liposomal encapsulation, offers a highly viable strategy to overcome these barriers, ultimately paving the way for next-generation, venom-inspired cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Ciencias Basicas, Facultad de Medicina, Universidad de La Frontera, Temuco 4780000, Chile.
- Department of Chemistry (RSAPS), The Assam Royal Global University, Guwahati 781035, Assam, India.
- Department of Chemistry, Universidad Tecnica Federico Santa Maria, Valparaíso 2340000, Chile.
- Department of Crop Protection, Faculty of Agriculture, University of Ilorin, Ilorin 240003, Nigeria.
ORCID-Profile: Ayorinde Victor Ogundele, Geetmani Singh Nongthombam, Héctor Hernán Silva, Oluwatoyin Adenike Fabiyi
Förderung
- Agencia Nacional de Investigación y Desarrollo
- ANID Chile
- Universidad de La Frontera, Temuco, Chile
Zitieren
APA
Ogundele, A. V., Nongthombam, G. S., Nwagu, A. D., Silva, H. H., & Fabiyi, O. A. (2026). Venom-Derived Enzyme Inhibitors as Anticancer Agents: Structure–Activity Relationships, Molecular Targets and Mechanistic Insights. Molecules. https://doi.org/10.3390/molecules31132398
Vancouver
Ogundele AV, Nongthombam GS, Nwagu AD, Silva HH, Fabiyi OA. Venom-Derived Enzyme Inhibitors as Anticancer Agents: Structure–Activity Relationships, Molecular Targets and Mechanistic Insights. Molecules. 2026. doi:10.3390/molecules31132398
BibTeX
@article{Ogundele2026,
author = {Ogundele, Ayorinde Victor and Nongthombam, Geetmani Singh and Nwagu, Adanna D and Silva, Héctor Hernán and Fabiyi, Oluwatoyin Adenike},
title = {Venom-Derived Enzyme Inhibitors as Anticancer Agents: Structure–Activity Relationships, Molecular Targets and Mechanistic Insights},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31132398}
}
EUVIMED